Emergent BioSolutions reported $276.6M in Sales Revenues for its fiscal quarter ending in December of 2023.





Sales Change Date
Acadia Pharmaceuticals USD 342M 34.04M Sep/2026
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
ALKERMES USD 480.13M 15.88M Sep/2026
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
Amarin USD 49.22M 451K Dec/2025
ANI Pharmaceuticals USD 290.77M 24.77M Sep/2026
BioMarin Pharmaceutical USD 1.03B 40M Sep/2026
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Emergent BioSolutions USD 276.6M 6.1M Dec/2023
Exelixis USD 658.69M 30M Sep/2026
Glaxosmithkline GBP 8.89B 1.2B Sep/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Ionis Pharmaceuticals USD 243M 25M Sep/2026
Ironwood Pharmaceuticals USD 113.04M 6.53M Jun/2026
Lexicon Pharmaceuticals USD 5.49M 8.69M Dec/2025
Lonza CHF 3.58B 63M Jun/2025
Merck USD 18.1B 1.5B Sep/2026
Moderna USD 1.31M 98.69M Sep/2026
Myriad Genetics USD 190.7M 9.7M Jun/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 1.12B 161M Sep/2026
Pacira USD 176.65M 15.75M Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
PTC Therapeutics USD 357.8M 3.2M Sep/2026
Sanofi EUR 14.44B 2.49B Sep/2026
Sarepta Therapeutics USD 381.4M 19.9M Sep/2026
United Therapeutics USD 832.5M 49.2M Sep/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024